Optimal biological dose: A systematic review in cancer phase I clinical trials
Số trang: 10
Loại file: pdf
Dung lượng: 692.62 KB
Lượt xem: 10
Lượt tải: 0
Xem trước 2 trang đầu tiên của tài liệu này:
Thông tin tài liệu:
Classical phase 1 dose-finding designs based on a single toxicity endpoint to assess the maximum tolerated dose were initially developed in the context of cytotoxic drugs. With the emergence of molecular targeted agents and immunotherapies, the concept of optimal biological dose (OBD) was subsequently introduced to account for efficacy in addition to toxicity.
Nội dung trích xuất từ tài liệu:
Optimal biological dose: A systematic review in cancer phase I clinical trials
Nội dung trích xuất từ tài liệu:
Optimal biological dose: A systematic review in cancer phase I clinical trials
Tìm kiếm theo từ khóa liên quan:
BMC Cancer Phase 1 clinical trial Dose finding study Optimal biological dose Cytotoxic drugs Recommended phase 2 doseTài liệu có liên quan:
-
Differences between physician and patient preferences for cancer treatments: A systematic review
13 trang 179 0 0 -
6 trang 171 0 0
-
Immune checkpoint inhibitors and their impact on liver enzymes and attenuation
7 trang 150 0 0 -
2011–2021 rising prevalence of HPV infection among oropharyngeal carcinoma in France
9 trang 135 0 0 -
12 trang 103 0 0
-
19 trang 81 0 0
-
17 trang 71 0 0
-
9 trang 48 0 0
-
9 trang 43 0 0
-
Investigating the prognostic and predictive value of the type II cystatin genes in gastric cancer
17 trang 43 0 0